Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-23-206349
Filing Date
2023-08-08
Accepted
2023-08-08 17:21:37
Documents
7
Effectiveness Date
2023-08-08

Document Format Files

Seq Description Document Type Size
1 S-8 d417002ds8.htm S-8 58749
2 EX-5.1 d417002dex51.htm EX-5.1 8548
3 EX-23.2 d417002dex232.htm EX-23.2 3034
4 EX-FILING FEES d417002dexfilingfees.htm EX-FILING FEES 27494
5 GRAPHIC g417002dsp011.jpg GRAPHIC 7187
6 GRAPHIC g417002g72i35.jpg GRAPHIC 1953
7 GRAPHIC g417002g90i06.jpg GRAPHIC 2891
  Complete submission text file 0001193125-23-206349.txt   116165
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-273813 | Film No.: 231152602
SIC: 8071 Services-Medical Laboratories